Ovulation Induction and Fertility Pharmacology: Prescribing Foundations
Core concept: Fertility medications alter ovulation or gonadotropin signaling; selection depends on the precise infertility diagnosis, endocrine evaluation, and safety monitoring.
Key clinical distinction: Medications that stimulate ovulation are not interchangeable with treatments for amenorrhea, hyperprolactinemia, hypogonadism, or contraception.
Prescribing priority: Establish a pregnancy-intent plan, investigate underlying causes, and coordinate specialist monitoring when indicated (Cieri-Hutcherson, 2026; Drugs Affecting the Reproductive System, n.d.).
Workup before treatment
Assess duration of attempted conception, menstrual and ovulatory patterns, pregnancy status, age, prior pregnancies, medications, and endocrine symptoms. Distinguish likely PCOS-related anovulation from other hormonal or reproductive causes. A complete infertility assessment may involve issues beyond ovulation and should be coordinated with an appropriate fertility service when the cause is unclear. Irregular menstruation alone does not establish an indication to start ovulation-induction medication (Cieri-Hutcherson, 2026).
Letrozole and clomiphene
Letrozole is used off-label to induce ovulation in selected patients with PCOS-related anovulation; its FDA-approved Femara indication concerns breast cancer and its continuous oncologic dosing must not be copied into fertility treatment. Clomiphene, in contrast, has a labeled anovulatory-infertility indication. A 2026-listed U.S. clomiphene citrate product label recommends 50 mg orally daily for five days for an initial cycle, with 100 mg daily for five days only if ovulation does not occur; escalation above 100 mg/day for five days is not recommended. Reevaluate after three courses without ovulation or three ovulatory responses without conception rather than continuing indefinitely. Before each cycle exclude pregnancy and ovarian enlargement/cysts; visual symptoms warrant stopping treatment and evaluation, and ovarian hyperstimulation/multifetal pregnancy are clinically significant risks. Product labeling is not a substitute for comprehensive infertility evaluation and an established monitoring protocol (Cieri-Hutcherson, 2026; ANI Pharmaceuticals, 2026; FDA, 2024, Femara).
Gonadotropins and GnRH-based regimens
Gonadotropins require diagnosis-specific dosing, ultrasound and/or estradiol monitoring, and a predefined cancellation plan. The U.S. Gonal-f RFF Redi-ject label for initial ovulation induction starts follitropin alfa at 75 international units subcutaneously daily for 14 days; if response is insufficient, subsequent titration may occur in increments up to 37.5 international units no more often than every seven days, with a labeled ovulation-induction ceiling of 300 international units/day and treatment generally not exceeding 35 days. These are product-label boundaries for a monitored cycle—not a universal FNP initiation protocol. Assisted reproductive technology follows a separate schedule. Withhold the hCG trigger if ultrasound or estradiol response indicates excessive ovarian-hyperstimulation risk; ovarian hyperstimulation, multiple pregnancy, and cycle cancellation must be addressed before injection is begun (EMD Serono, 2025; Cieri-Hutcherson, 2026).
Other hormonal causes of infertility
Hyperprolactinemia can require a dopamine agonist, often cabergoline, after an etiologic evaluation. Conversely, exogenous testosterone can suppress spermatogenesis in an individual with testes and should not be prescribed as a fertility-enhancing strategy. For PCOS, metabolic management may improve ovulatory function, but pharmacotherapy is only one part of individualized preconception care (Cieri-Hutcherson, 2026).
Define the boundary between primary care workup and monitored induction
Before considering ovulation induction, determine whether the problem is likely anovulation, assess pregnancy intent and relevant endocrine or metabolic factors, and consider whether additional infertility evaluation is required. Apply current U.S. clomiphene dose limits and stopping criteria. Letrozole is used off-label for selected PCOS-related anovulation; its FDA-approved breast-cancer dosing is not an infertility protocol. The treating fertility service should determine monitoring and cycle-cancellation responsibilities, particularly when conception does not follow demonstrated ovulation (Cieri-Hutcherson, 2026; ANI Pharmaceuticals, 2026; U.S. Food and Drug Administration, 2024).
Do not use a hormonal mechanism as a fertility indication
Combined contraception regulates bleeding but suppresses ovulation, whereas letrozole or clomiphene promotes ovulation and can lead to multiple gestation. Metformin is useful for metabolic disease in selected patients but should not be promised as equivalent to ovulation induction. Gonadotropins require close monitoring for ovarian hyperstimulation and multifetal pregnancy; primary care follow-up should coordinate pregnancy testing, side effects, and timely specialist review rather than independently escalating injection doses based on an incomplete source (Cieri-Hutcherson, 2026; Drugs Affecting the Reproductive System slides, n.d.).
Clinical application
A 30-year-old with PCOS seeks pregnancy after nine months of trying and reports infrequent menstrual cycles. Rather than immediately prescribing letrozole, establish pregnancy status, characterize her ovulatory pattern, review relevant endocrine and metabolic contributors, and ask whether other fertility factors have been assessed. Explain that letrozole may be used off-label for PCOS-related anovulation, but restoring ovulation does not establish that every cause of infertility has been addressed. Coordinate the wider evaluation and monitored induction plan with a fertility service; if ovulation occurs without conception, reassess the diagnosis and treatment pathway instead of increasing the dose empirically (Cieri-Hutcherson, 2026).
High-yield distinctions
Letrozole and clomiphene have different mechanisms. Ovulation-inducing medicines require pregnancy-intent counseling and monitoring. Testosterone may worsen rather than improve male fertility.
Related YourDNP Resources
Pharmacology learning hub · Amenorrhea and PCOS · Testosterone therapy · Combined hormonal contraception
Content last reviewed:
References
ANI Pharmaceuticals, Inc. (2026). Clomiphene citrate tablets, USP 50 mg: U.S. product labeling. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b56e04f0-490d-4f10-a0ed-31c288f4f4c5
Cieri-Hutcherson, N. E. (2026). Menstruation-related disorders and menopause. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 50). McGraw Hill.
Drugs affecting the reproductive system [PowerPoint slides, Chapter 20]. (n.d.). Pharmacotherapeutics for advanced practice nurse prescribers (5th ed.). User-supplied instructional resource.
EMD Serono, Inc. (2025). Gonal-f RFF Redi-ject (follitropin alfa): U.S. prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6d11c45-b502-478e-bb28-2ff596ea259c
U.S. Food and Drug Administration. (2024, December). Femara (letrozole): Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020726s043lbl.pdf